{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T09:14:51Z","timestamp":1778145291964,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.xkme.2026.101326","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T08:15:15Z","timestamp":1773303315000},"page":"101326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Minimal Change Disease Following B-Cell Maturation Antigen\u2013Directed Chimeric Antigen Receptor T-Cell Therapy"],"prefix":"10.1016","volume":"8","author":[{"given":"Kiran","family":"Shivaraj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Mamlouk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Tchakarov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krina","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ala","family":"Abudayyeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.xkme.2026.101326_bib1","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.xkme.2026.101326_bib2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xkme.2026.101326_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215949","article-title":"BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma","volume":"553","author":"Yang","year":"2023","journal-title":"Cancer Lett"},{"issue":"5","key":"10.1016\/j.xkme.2026.101326_bib4","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.ekir.2021.02.013","article-title":"Systematic review of risk factors and incidence of acute kidney injury among patients treated with CAR-T cell therapies","volume":"6","author":"Kanduri","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"4","key":"10.1016\/j.xkme.2026.101326_bib5","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s004670050760","article-title":"Interleukin-8 alters glomerular heparan sulfate glycosaminoglycan chain size and charge in rats","volume":"14","author":"Garin","year":"2000","journal-title":"Pediatr Nephrol"},{"issue":"11","key":"10.1016\/j.xkme.2026.101326_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21113886","article-title":"A new era in endothelial injury syndromes: toxicity of CAR-T cells and the role of immunity","volume":"21","author":"Gavriilaki","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.xkme.2026.101326_bib7","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.xkme.2021.06.011","article-title":"Collapsing focal segmental glomerulosclerosis and acute kidney injury associated with chimeric antigen receptor T-cell (CAR-T) therapy: a case report","volume":"3","author":"Acharya","year":"2021","journal-title":"Kidney Med"},{"key":"10.1016\/j.xkme.2026.101326_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5414\/CNCS111045","article-title":"Thrombotic microangiopathy following chimeric antigen receptor T-cell therapy","volume":"11","author":"Wu","year":"2023","journal-title":"Clin Nephrol Case Stud"},{"key":"10.1016\/j.xkme.2026.101326_bib9","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fmed.2018.00170","article-title":"Molecular and cellular mechanisms for proteinuria in minimal change disease","volume":"5","author":"Bertelli","year":"2018","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"10.1016\/j.xkme.2026.101326_bib10","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1046\/j.1523-1755.2000.00870.x","article-title":"Dominant T cells in idiopathic nephrotic syndrome of childhood","volume":"57","author":"Frank","year":"2000","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.xkme.2026.101326_bib11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000533695","article-title":"Review of the role of rituximab in the management of adult minimal change disease and immune-mediated focal and segmental glomerulosclerosis","volume":"3","author":"Aslam","year":"2023","journal-title":"Glomerular Dis"},{"issue":"1","key":"10.1016\/j.xkme.2026.101326_bib12","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1111\/bjh.19152","article-title":"Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function","volume":"204","author":"Mamlouk","year":"2024","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.xkme.2026.101326_bib13","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.xkme.2026.101326_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol Ther Oncolytics"},{"issue":"4","key":"10.1016\/j.xkme.2026.101326_bib15","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.xkme.2026.101326_bib16","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/mt.2013.17","article-title":"Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity","volume":"21","author":"Lamers","year":"2013","journal-title":"Mol Ther"},{"issue":"10297","key":"10.1016\/j.xkme.2026.101326_bib17","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.xkme.2026.101326_bib18","article-title":"Immune cell composition in normal human kidneys","volume":"10","author":"Park","year":"2020","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.xkme.2026.101326_bib19","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.ekir.2020.09.027","article-title":"Urinary CD 80 in nephrotic syndrome: a biomarker to distinguish minimal change disease from other glomerular diseases","volume":"5","author":"Mishra","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1016\/j.xkme.2026.101326_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2021.10.009","article-title":"Histiocytic glomerulopathy associated with hemophagocytic lymphohistiocytosis","volume":"4","author":"Dokouhaki","year":"2022","journal-title":"Kidney Med"},{"key":"10.1016\/j.xkme.2026.101326_bib21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12882-015-0217-z","article-title":"Acute kidney injury induced by thrombotic microangiopathy in a patient with hemophagocytic lymphohistiocytosis","volume":"17","author":"Bae","year":"2016","journal-title":"BMC Nephrol"},{"issue":"23","key":"10.1016\/j.xkme.2026.101326_bib22","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1182\/blood.2020008865","article-title":"Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526000877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526000877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T08:39:04Z","timestamp":1778143144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059526000877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2590059526000877"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101326","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Minimal Change Disease Following B-Cell Maturation Antigen\u2013Directed Chimeric Antigen Receptor T-Cell Therapy","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101326","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101326"}}